The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial

• Główni autorzy: Apostolis Papaefthymiou (Autor), Styliani Sarrou (Autor), Konstantinos Pateras (Autor), Ilias D. Vachliotis (Autor), Georgios Agrotis (Autor), Ioanna-Konstantina Sgantzou (Autor), Georgios Perifanos (Autor), Andreas Kapsoritakis (Autor), Matthaios Speletas (Autor), Marianna Vlychou (Autor), George N. Dalekos (Autor), Spyros Potamianos (Autor), Antonis Goulas (Autor), Jannis Kountouras (Autor), Stergios A. Polyzos (Autor)
• Format: Książka
• Wydane: MDPI AG, 2024-10-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biolog...